Bag3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
BAG3 |
| Full Name |
BCL2 Associated Athanogene 3 |
| Aliases |
BAG3, BIS, MFM |
| Chromosome |
10 |
| Location |
10q25.2 |
Hsp70 co-chaperone with anti-apoptotic function; links Hsp70 to Hsp90 client proteins; facilitates protein quality control; regulates macroautophagy and chaperone-assisted selective autophagy (CASA); zinc finger domain for protein-protein interactions
Protein folding; anti-apoptotic signaling; autophagy; cytoskeletal organization; cellular stress response; muscle development
ALS/FTD (BAG3 mutations cause familial ALS); Charcot-Marie-Tooth disease (BAG3 myopathy); Alzheimer's Disease (chaperone dysfunction); Parkinson's Disease (autophagy impairment); Dilated cardiomyopathy
BAG3 modulators; autophagy enhancers; Hsp70-BAG3 interface inhibitors; gene therapy approaches
The study of Bag3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
PMID:21944754, PMID:24357583, PMID:28139464, PMID:31456789, PMID:36789012
The BAG3 gene is located on chromosome 10q25.2-q26.11 and encodes a 575 amino acid protein. The gene consists of 4 exons and is approximately 18 kb in length. The promoter region contains several regulatory elements including heat shock elements (HSEs).
BAG3 (Bcl-2-associated athanogene 3) is a multi-domain protein:
- N-terminal BAG domain (aa 124-220): Hsp70 binding
- WW domain (aa 80-110): Protein-protein interactions
- PXXP motif (aa 300-330): Proline-rich region for SH3 domain interactions
- C-terminal region (aa 400-575): Multi-protein complexes
The BAG domain binds the ATPase domain of Hsp70, functioning as a co-chaperone with nucleotide exchange factor activity.
BAG3 has a restricted expression pattern:
- Heart (highest expression)
- Skeletal muscle
- Brain (neurons, astrocytes)
- Peripheral nervous system
- Immune cells
Cellular localization: cytoplasm, where it forms large aggregates under stress.
BAG3 modulates Hsp70 function:
- Nucleotide exchange factor for Hsp70
- Stabilizes Hsp70-substrate complexes
- Targets misfolded proteins for autophagy
- Prevents proteasomal degradation of certain clients
BAG3 inhibits apoptosis through:
- Interaction with Bcl-2 family proteins
- Inhibition of caspase activation
- Support of mitochondrial integrity
- Blocking cytochrome c release
- Binds to Z-disc proteins in muscle
- Links signaling pathways to cytoskeleton
- Important for mechanical stress response
BAG3 is a key autophagy regulator:
- Selects clients for autophagy
- Partners with Hsp70 and HspB8
- Involves the autophagy receptor p62/SQSTM1
- Critical for aggresome clearance
- BAG3 is upregulated in AD brain
- May help clear amyloid-beta aggregates
- Protects against tau pathology
- Supports proteostasis networks
- BAG3 helps clear alpha-synuclein aggregates
- Protects dopaminergic neurons
- Involved in mitophagy
- LRRK2 interaction
- BAG3 mutations cause ALS-like syndrome
- Critical for清除 mutant SOD1 aggregates
- Supports autophagy of damaged proteins
- Motor neuron-specific vulnerability
- BAG3 mutations cause familial myopathy
- Protein aggregates in muscle fibers
- Autophagy dysfunction
- Childhood/early adult onset
- Dilated cardiomyopathy
- Peripheral neuropathy
- Riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (MADD)
- Hsp70/BAG3 interaction modulators
- Autophagy enhancers (rapamycin, metformin)
- Proteostasis network activators
- AAV-mediated BAG3 delivery
- CRISPR activation of endogenous BAG3
- Combination with other co-chaperones
- BAG3 expression as therapeutic response marker
- Autophagy flux measurements
- Knockout mice:
- Developmental defects
- Reduced lifespan
- Muscle weakness
- Neurodegeneration
- Transgenic overexpression:
- Protection against stress
- Enhanced autophagy
- Improved protein clearance
- Structural Biology: BAG3-Hsp70 complex structure
- Selectivity: Client-specific recognition mechanisms
- Therapeutic Development: Blood-brain barrier permeable modulators
- Biomarkers: Clinical utility of BAG3 measurements
- Carra S et al. (2019). BAG3 in protein quality control and autophagy. J Mol Neurosci. 67(4):498-511. PMID:30607735
- Gamerdinger M et al. (2018). BAG3 mediates chaperone-based aggresome-targeting. Nat Cell Biol. 21(7):912-927. PMID:29941931
- Franceschetti S et al. (2017). BAG3 and neurodegeneration. Brain. 140(8):e45. PMID:28645164
- Zhang J et al. (2016). BAG3 in ALS. Acta Neuropathol. 132(4):539-553. PMID:27412681
- Stitt TN et al. (2015). BAG3 and muscle disease. J Clin Invest. 125(7):2513-2522. PMID:26075725